Find a DoctorGet Care Now
MyChart

Contrast

Contact

Share

Donate

MyChart

Help

Smilow Cancer Hospital at Yale New Haven celebrates Phase 1 clinical trials infusion center dedication with ribbon cutting

Smilow Cancer Hospital at Yale New Haven celebrates Phase 1 clinical trials infusion center dedication with ribbon cutting

Wednesday, September 7, 2016

New Haven, CT (Sept. 8, 2016) –Smilow Cancer Hospital at Yale New Haven held a ribbon cutting ceremony today, officially opening the new Phase I Clinical Trial Infusion Center. The Phase 1 clinic is the only one of its kind in Connecticut.

“I am incredibly proud to have the opportunity to care for my patients in this beautiful, dedicated space at Smilow Cancer Hospital,” said Patricia LoRusso, MD, professor of Medicine (Medical Oncology) and associate director of Innovative medicine at Yale Cancer Center. “Phase I clinical trials require a specialized team of clinicians to provide access to the most advanced cancer therapies to patients. This outstanding new facility gives our team the physical resources they need to continually focus on our patients.”

The new Phase I Clinical Trial Infusion Center will provide essential options for patients with advanced cancers seeking new therapies when standard treatments are no longer an option. Many phase I trials are offered with new targeted therapies that have been proved effective in research, others test new combinations of approved therapies and new applications. In collaboration with Yale Cancer Center, Smilow Cancer Hospital currently has over 40 phase I clinical trials available to patients.

“With this new center, we are seeing the true integration of science and clinical research,” said Rogerio Lilenbaum, chief medical officer, Smilow Cancer Hospital at Yale New Haven. “This is a true clinical research unit where innovation and cutting-edge research meet to offer patients new hope and new treatment strategies that otherwise might not be available to them. This is a great day for cancer patients in the state of Connecticut bringing new hope for everybody.”

Clinical trials are research studies that test how well new medical approaches work in people. Each study answers scientific questions and tries to find better ways to prevent, screen for, diagnose or treat a disease. People who take part in cancer clinical trials have an opportunity to contribute to knowledge of, and progress against, cancer. They also receive up-to-date care from experts.

Smilow Cancer Hospital at Yale New Haven is part of the nationally recognized Yale New Haven Hospital, and is affiliated with Yale Cancer Center (YCC), one of only 51 National Cancer Institute (NCI)-designated comprehensive cancer centers in the nation and the only such center in Connecticut. Smilow Cancer Hospital, the most comprehensive cancer facility in New England, includes private inpatient rooms, multidisciplinary outpatient treatment centers, 12 operating rooms, infusion suites, diagnostic imaging services, and specialized women's and children’s services. Smilow Cancer Hospital also operates a dozen outpatient care centers across Connecticut. YCC and Smilow Cancer Hospital are members of the National Comprehensive Cancer Network (NCCN), an alliance of 28 cancer centers in the U.S., whose mission is to improve the quality, effectiveness and efficiency of oncology care. www.ynhh.org/smilow.

Similar Articles

9/30/2021

Margaret Gilshannon named Deputy Director for Finance & Administration at Yale Cancer Center

New Haven, CT (September 30, 2021)— Margaret Gilshannon, MHA, has been appointed Deputy Director for Finance & Administration at Yale Cancer Center. Gilshannon joined Yale Cancer Center last year as Senior Director of Finance & Administration, while also leading the Integrated Business Operations for the Department of Pathology at Yale School of Medicine.

9/25/2021

Yale Cancer Center Study Demonstrates Efficacy of Risk Calculator in Treating Geriatric Patients with Cancer

New Haven, CT (Sept. 25, 2021) - Yale Cancer Center researchers show using a validated risk calculator helped drive informed treatment decisions in older patients with cancer.

9/17/2021

Yale Cancer Center Study Shows New Drug Combinations Improve Outcomes for Patients with Advanced Lung Cancer

New Haven, CT - New findings from a large study led by researchers at Yale Cancer Center shows the addition of the drugs oleclumab or monalizumab to durvalumab improved progression-free survival for patients with locally advanced non-small cell lung cancer (NSCLC).